This submission builds on the depth and versatility of BOTOX Cosmetic and reflects our continued investment in advancing aesthetic medicine
Blinded interim analysis shows 37% composite remission rate for drug that aims to treat relapsed or refractory acute myeloid leukaemia
The study reported a hazard ratio of 0.99 versus placebo
The trials represent the largest Phase 3 clinical program to date evaluating an oral systemic therapy for the disease
Recognition highlights company's commitment to accessible workplaces and inclusive clinical research
The findings could significantly expand the number of patients eligible for targeted therapy
Merck said its strategy combines early generic licensing, regional manufacturing partnerships in Africa and Latin America
203-day study with ICMR to evaluate the efficacy and safety of the oral therapy in 164 patients with sickle cell disease
The treatment also produced statistically significant improvements in nail psoriasis severity compared with placebo
The SIGMA trial will assess GAMUNEX-C, an intravenous immunoglobulin
The BD-Ebov trial, led by Oxford Vaccine Group, will evaluate the safety and immune response of the ChAdOx1 BDBV vaccine in 50 healthy volunteers aged 18 to 55
The experimental therapy is designed to target seven tumor antigens commonly shared across multiple cancer types
No serious treatment-related adverse events observed in first 13 patients receiving ENV-105 with AstraZeneca's Tagrisso in Phase I study.
The first-line approval is backed by results from the Phase 3 BREAKWATER trial, which demonstrated that the cetuximab–encorafenib–FOLFOX combination delivered statistically significant and clinically meaningful improvements
The majority of participants also rated the denecimig pen-injector positively, with 94.1% of 185 participants describing it as easy or very easy to use and 89.7% reporting it was quick
This, after positive FDA feedback on neuropathic corneal pain program
The potential impact of the findings is particularly significant in episodic migraine, which represents a larger patient population than chronic migraine
The treatment effect emerged early and continued to build over time, with statistically significant improvement observed as soon as Day 64 and maintained through Week 24
The results come from two Phase 1/2 trials evaluating zoldonrasib both alongside standard chemotherapy in first-line patients and in combination with daraxonrasib in previously treated disease
Subscribe To Our Newsletter & Stay Updated
